Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance
Authors:
Open Access
- 6 June 2013
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 4 (5) , 206-222
Abstract
Acute upper gastrointestinal (GI) bleeding is a common medical emergency and associated with significant morbidly and mortality. The risk of bleeding from peptic ulceration and oesophagogastric varices can be reduced by appropriate primary and secondary preventative strategies. Helicobacter pylori eradication and risk stratification with appropriate gastroprotection strategies when used with antiplatelet drugs and nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in preventing peptic ulcer bleeding, whilst endoscopic screening and either nonselective beta blockade or endoscopic variceal ligation are effective at reducing the risk of variceal haemorrhage. For secondary prevention of variceal haemorrhage, the combination of beta blockade and endoscopic variceal ligation is more effective. Recent data on the possible interactions of aspirin and NSAIDs, clopidogrel and proton pump inhibitors (PPIs), and the increased risk of cardiovascular adverse events associated with all nonaspirin cyclo-oxygenase (COX) inhibitors have increased the complexity of choices for preventing peptic ulcer bleeding. Such choices should consider both the GI and cardiovascular risk profiles. In patients with a moderately increased risk of GI bleeding, a NSAID plus a PPI or a COX-2 selective agent alone appear equivalent but for those at highest risk of bleeding (especially those with previous ulcer or haemorrhage) the COX-2 inhibitor plus PPI combination is superior. However naproxen seems the safest NSAID for those at increased cardiovascular risk. Clopidogrel is associated with a significant risk of GI haemorrhage and the most recent data concerning the potential clinical interaction of clopidogrel and PPIs are reassuring. In clopidogrel-treated patients at highest risk of GI bleeding, some form of GI prevention is indicated.Keywords
This publication has 99 references indexed in Scilit:
- Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular systemProceedings of the National Academy of Sciences, 2012
- Endoscopic Management of Portal HypertensionInternational Journal of Hepatology, 2012
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissionsGut, 2011
- Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1Proceedings of the National Academy of Sciences, 2009
- Diclofenac and acute myocardial infarction in patients with no major risk factorsBritish Journal of Clinical Pharmacology, 2007
- Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology, 2007
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000